Context
BlueBee is a Netherlands-based SaaS provider of cloud-based genomics data analysis solutions.
BlueBee serves pharmaceutical companies, assay providers and instrument manufacturers as well as government-funded research initiatives, in Europe and the US.
In order to accelerate BlueBee’s platform adoption, the Company contemplated either a sizeable fundraising or a synergetic M&A deal.
US-based DNA sequencing world-leader Illumina recognized the value of BlueBee’s technology and decided to integrate it to its own solution through the acquisition of the Company.
About BlueBee
BlueBee is a global bioinformatics software solutions provider offering fit-for-purpose configurability on its BlueBee Genomics Platform. BlueBee data analysis solutions serve to analyze, interpret, report, and learn from aggregated data, for research and diagnostic assay manufacturers, high-throughput service providers, large project initiatives, and biopharma.
Deal Team
Should you want to know more about this transaction, you can contact one of the team members above
Bryan, Garnier & Co acts as Sole M&A and Strategic Advisor to BlueBee on its sale to Illumina
Bryan, Garnier & Co acted as sole M&A and Strategic Advisor to BlueBee on its sale to Illumina.
Bryan, Garnier & Co assisted BlueBee and its shareholders in its strategic review and throughout the acquisition process. In a very competitive process involving both international strategic and financial buyers, Bryan, Garnier & Co’s intelligence and deal experience enabled BlueBee to optimize the terms of the transaction.
Hans Cobben, CEO, BlueBee comments: “Bryan, Garnier & Co has been very professional in leading the process, involving candidates from all over the world. Their dedication generated several pertinent marks of interest for our company. They managed to maintain drive and focus amidst the uncertainty caused by the Covid-19 pandemic and delivered a very swift 3-month M&A transaction. Bryan, Garnier & Co played a vital role in this transaction. Their involvement throughout the process took away a great deal of pressure from our internal resources, allowing us to focus on running and further developing our business while preparing for integration with Illumina. I would highly recommend them”.
This transaction exemplifies how Bryan, Garnier & Co’s leading healthcare practice enabled a focused and swift three-month process, in a highly volatile context due to the Covid-19 pandemic, to deliver a very successful transaction.
Share